The CASZ1 Knockout A2780 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population for studying the tumor suppressor transcription factor CASZ1. This polyclonal knockout model is generated by CRISPR/Cas9-mediated target-gene disruption, creating a heterogeneous loss-of-function model that ablates CASZ1 protein expression in the A2780 ovarian carcinoma host cell line. The polyclonal nature encompasses a diverse allelic spectrum of disruptions, enabling functional analysis without clonal selection, and is suitable for population-level assays that assess the collective impact of CASZ1 loss on cellular phenotypes.
The host cell line A2780 is a widely utilized human ovarian adenocarcinoma model derived from an untreated patient, displaying epithelial morphology and retaining key genetic features of high-grade serous ovarian cancer. A2780 cells express functional p53 and exhibit robust proliferation, migration, and invasion capabilities, making them an ideal platform for oncogene and tumor suppressor investigations. This cellular background allows researchers to directly evaluate the consequences of CASZ1 depletion in a clinically relevant ovarian cancer microenvironment and to compare with wild-type controls to delineate CASZ1-dependent phenotypes.
CASZ1 is a zinc-finger transcription factor that orchestrates gene expression programs governing cell cycle arrest, apoptosis, and differentiation. Mechanistically, CASZ1 transcriptionally represses key oncogenes such as MYC and MDM2, and modulates Rho GTPase signaling through direct regulation of RHOA. Its activity is influenced by upstream regulators including the cardiac transcription factors GATA4 and TBX5, as well as by DNA methylation at its promoter. CASZ1 interacts with chromatin-modifying complexes such as HDACs and components of the NuRD complex, integrating into Notch, p53, and RhoA signaling networks. Loss of CASZ1 disrupts these regulatory circuits, leading to aberrant expression of downstream targets and promoting unchecked proliferation and enhanced motility.
In the A2780 ovarian carcinoma context, knockout of CASZ1 is predicted to exacerbate oncogenic traits by relieving transcriptional repression of MYC and MDM2, thereby enhancing cell cycle progression and inhibiting p53-mediated apoptosis. Concomitant activation of RHOA-dependent signaling may further potentiate cytoskeletal rearrangements essential for migration and invasion. This polyclonal knockout model thus recapitulates key aspects of ovarian cancer progression where CASZ1 silencing or deletion is observed, providing a valuable tool to dissect its tumor-suppressive functions and to identify vulnerabilities that arise upon its loss.
This product is ideally suited for tumor suppressor studies, ovarian cancer modeling, and transcriptional regulation analysis. Researchers can employ a range of assays including western blotting and RT-qPCR to confirm CASZ1 ablation and monitor target gene expression, apoptosis assays to quantify cell death, and migration/invasion and proliferation assays to assess functional consequences. The polyclonal knockout cells enable robust statistical comparisons in dose-response experiments, drug screening, and pathway interrogation without the bias of single clonal expansion. For further details, please contact Ascent Research.
